参考文献/References:
[1]Kim D. Pulmonary hypertension[J]. Med Clin North Am ,2019,103(3):413-423.
[2]Boucly A,Weatherald J,Savale L,et al. Risk assessment,prognosis and guideline implementation in pulmonary arterial hypertension[J]. Eur Respir J,2017,50(2).pii:1700889.
[3]Lacalle RA,Blanco R,Carmona-Rodriguez L,et al. Chemokine receptor signaling and the hallmarks of cancer[J]. Int Rev Cell Mol Biol,2017,331:181-244.
[4]Mamazhakypov A,Viswanathan G,Lawrie A,et al. The role of chemokines and chemokine receptors in pulmonary arterial hypertension[J]. Br J Pharmacol,2019,10(Epub ahead of print)
[5]Hughes CE,Nibbs RJB. A guide to chemokines and their receptors[J]. FEBS J,2018,285(16):2944-2971.
[6]David BA,Kubes P. Exploring the complex role of chemokines and chemoattractants in vivo on leukocyte dynamics[J]. Immunol Rev,2019,289(1):9-30.
[7]Isles HM,Herman KD,Robertson AL,et al. The CXCL12/CXCR4 signaling axis retains neutrophils at inflammatory sites in zebrafish[J]. Front Immunol,2019,10:1784.
[8]Bordenave J,Thuillet R,Tu L,et al. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats[J]. Cardiovasc Res,2019,7.pii:cvz153.
[9]Zhang T,Kawaguchi N,Hayama E,et al. High expression of CXCR4 and stem cell markers in a monocrotaline and chronic hypoxia-induced rat model of pulmonary arterial hypertension[J]. Exp Ther Med,2018,15(6):4615-4622.
[10]Wei L,Zhang B,Cao W,et al. Inhibition of CXCL12/CXCR4 suppresses pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia[J]. J Recept Signal Transduct Res,2015,35(4):329-339.
[11]Dai Z,Li M,Wharton J,et al. Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2α[J]. Circulation,2016,133(24):2447-2458.
[12]Heresi GA,Aytekin M,Newman J,et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension:marker of improved survival[J]. Lung,2010,188(3):191-197.
[13]Zabini D,Nagaraj C,Stacher E,et al. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction[J]. PLoS One,2012,7(8):e43793.
[14]George PM,Oliver E,Dorfmuller P,et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension[J]. Circ Res,2014,114(4):677-688.
[15]Farkas D,Thompson AAR,Bhagwani AR,et al. Toll-like receptor 3 is a therapeutic target for pulmonary hypertension[J]. Am J Respir Crit Care Med,2019,199(2):199-210.
[16]Sanchez O,Marcos E,Perros F,et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2007,176(10):1041-1047.
[17]Jiang S,Wang Q,Wang Y,et al. Blockade of CCL2/CCR2 signaling pathway prevents inflammatory monocyte recruitment and attenuates OVA-Induced allergic asthma in mice[J]. Immunol Lett,2019,214:30-36.
[18]Yu YR,Mao L,Piantadosi CA,et al. CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension[J]. Am J Respir Cell Mol Biol,2013,48(5):647-654.
[19]Liu W,Jiang L,Bian C,et al. Role of CX3CL1 in diseases[J]. Arch Immunol Ther Exp (Warsz),2016,64(5):371-383.
[20]Balabanian K,Foussat A,Dorfmüller P,et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2002,165(10):1419-1425.
[21]Zhang J,Yang W,Luo B,et al. The role of CX(3)CL1/CX(3)CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome[J]. J Hepatol,2012,57(4):752-758.
[22]Amsellem V,Abid S,Poupel L,et al. Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 chemokine systems in hypoxic pulmonary hypertension[J]. Am J Respir Cell Mol Biol,2017,56(5):597-608.
[23]Florentin J,Coppin E,Vasamsetti SB,et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes[J]. J Immunol,2018,200(10):3612-3625.
[24]Olsson KM,Olle S,Fuge J,et al. CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]. Respir Res,2016,17:21.
[25]Yang T,Li ZN,Chen G,et al. Increased levels of plasma CXC-Chemokine Ligand 10,12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension[J]. Heart Lung,2014,43(4):322-327.
[26]Hoffmann-Vold AM,Hesselstrand R,Fretheim H,et al. CCL21 as a potential serum biomarker for pulmonary arterial hypertension in systemic sclerosis[J]. Arthritis Rheumatol,2018,70(10):1644-1653.
[27]Larsen KO,Yndestad A,Sjaastad I,et al. Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation[J]. Am J Physiol Lung Cell Mol Physiol,2011,301(1):L50-59.
[28]Amsellem V,Lipskaia L,Abid S,et al. CCR5 as a treatment target in pulmonary arterial hypertension[J]. Circulation,2014,130(11):880-891.
[29]Cheng YH,Eby JM,LaPorte HM,et al. Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function[J]. PLoS One,2017,12(11):e0187949.
[30]Tielemans B,Delcroix M,Belge C,et al. TGFbeta and BMPRⅡsignalling pathways in the pathogenesis of pulmonary arterial hypertension[J]. Drug Discov Today,2019,24(3):703-716.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(3):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(3):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[9]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[10]刘雪鸢 徐燕萍 殷跃辉.交感神经去除术在肺动脉高压治疗中的研究进展[J].心血管病学进展,2020,(5):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]
LIU Xueyuan,XU Yanping,YIN Yuehui.Sympathetic Denervation in Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]